ArticlePloS one2014
Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.Clinical and molecular hepatology · 2018Guideline
- Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).Wiener klinische Wochenschrift · 2017Guideline
- Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial.The American journal of tropical medicine and hygiene · 2018Trial
- Trial
- Article
- Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota.Antibiotics (Basel, Switzerland) · 2023Review
- Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV).Wiener klinische Wochenschrift · 2023Article
- Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.Journal of clinical medicine · 2023Review
- Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions.World journal of gastroenterology · 2022Review
- The Use of Rifaximin in Patients With Cirrhosis.Hepatology (Baltimore, Md.) · 2021Review
- The Role of the Microbiome in Liver Cancer.Cancers · 2021Review
- Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.Nature reviews. Gastroenterology & hepatology · 2021Review
- Unresolved issues in the prophylaxis of bacterial infections in patients with cirrhosis.World journal of hepatology · 2018Article
- Novel perspectives in the management of decompensated cirrhosis.Nature reviews. Gastroenterology & hepatology · 2018Review
- Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure.Visceral medicine · 2018Review
- Rifaximin has the potential to prevent complications of cirrhosis.Therapeutic advances in gastroenterology · 2018Article
- The gut microbiome and liver cancer: mechanisms and clinical translation.Nature reviews. Gastroenterology & hepatology · 2017Review
- Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review.BMJ open gastroenterology · 2017Article
- Use of rifaximin in gastrointestinal and liver diseases.World journal of gastroenterology · 2016Review
- Novel prevention strategies for bacterial infections in cirrhosis.Expert opinion on pharmacotherapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRifaximin is a non-absorbable antibiotic used to prevent relapses of hepatic encephalopathy which may also be a candidate for prophylaxis of spontaneous bacterial peritonitis (SBP).
aimTo detect the impact of rifaximin on the occurrence and characteristics of SBP.
methodsWe prospectively studied all hospitalized patients that underwent a diagnostic paracentesis in our department from March 2012 to April 2013 for SBP and recorded all clinical data including type of SBP prophylaxis, prior use of rifaximin, concomitant complications of cirrhosis, as well as laboratory results and bacteriological findings. Patients were divided into the following three groups: no antibiotic prophylaxis, prophylaxis with rifaximin or with systemically absorbed antibiotic prophylaxis.
resultsOur study cohort comprised 152 patients with advanced liver cirrhosis, 32 of whom developed SBP during the study period. As expected, our study groups differed regarding a history of hepatic encephalopathy and SBP before inclusion into the study. None of the 17 patients on systemic antibiotic prophylaxis developed SBP while 8/27 patients on rifaximin and 24/108 without prophylaxis had SBP (p = 0.02 and p = 0.04 versus systemic antibiotics, respectively). In general, episodes of SBP were similar for patients treated with rifaximin and those without any prophylaxis. However, Escherichia coli and enterococci were dominant in the ascites of patients without any prophylaxis, while mostly klebsiella species were recovered from the ascites samples in the rifaximin group.
conclusionRifaximin pretreatment did not lead to a reduction of SBP occurrence in hospitalized patients with advanced liver disease. However, the bacterial species causing SBP were changed by rifaximin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.